Home › Search
Search
314 results for "lecanemab".
Research summaries 285
Showing the best 200 of 285, 51–60, page 6 of 20. Filter these by subject, year and score in the research library →
-
Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting systemResearch summary
Research summaries · alzhub.org/study/comparison-of-safety-of-lecanemab-and-aducanumab-a-real-world-40520157
… drug events (ADEs) of lecanemab and aducanumab separately, there is a lack of comparison between these two drugs, and no exploration of gender differences. This study aims to compare the adverse reaction signals of lecanemab and …
-
Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort studyResearch summary
Research summaries · alzhub.org/study/dynamic-changes-in-plasma-biomarkers-of-alzheimer-s-disease-in-42785333
The study included 197 patients in whom lecanemab infusions had been started (lecanemab group), as well as 173 patients in whom lecanemab had been ordered but not yet started, who were combined with 1139 research participants …
-
Eficacia del lecanemab en el tratamiento de la Enfermedad de Alzheimer: revisión de la literatura (2015-2025)Research summary
Research summaries · alzhub.org/study/eficacia-del-lecanemab-en-el-tratamiento-de-la-enfermedad-de-cf778e0b
Este ensayo tiene como objetivo analizar la eficacia del lecanemab como terapia modificadora de la enfermedad de Alzheimer (EA). This literature review aims to analyse the efficacy of lecanemab as a disease-modifying therapy for …
-
Eficacia del lecanemab en el tratamiento de la Enfermedad de Alzheimer: revisión de la literatura (2015-2025)Research summary
Research summaries · alzhub.org/study/eficacia-del-lecanemab-en-el-tratamiento-de-la-enfermedad-de-ee62b24d
Este ensayo tiene como objetivo analizar la eficacia del lecanemab como terapia modificadora de la enfermedad de Alzheimer (EA). This literature review aims to analyse the efficacy of lecanemab as a disease-modifying therapy for …
-
Research summaries · alzhub.org/study/higher-phosphorylated-tau-levels-predict-cognitive-decline-and-41276859
Background Lecanemab was recently approved for the treatment of patients with early Alzheimer's disease (AD) and demonstrated reduced senile amyloid plaque and less decline on the measures of cognition and function in clinical …
-
Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemabResearch summary
Research summaries · alzhub.org/study/ischemic-stroke-associated-with-amyloid-related-imaging-abnormalities-39215494
Introduction Anti-amyloid antibody therapies such as lecanemab are increasingly being used to treat Alzheimer's disease (AD). These therapies are associated with a high rate of amyloid-related imaging abnormalities (ARIA). …
-
Lecanemab Therapy Use Patterns for Alzheimer's Disease Among Early Initiators in a Large National Health PlanResearch summary
Research summaries · alzhub.org/study/lecanemab-therapy-use-patterns-for-alzheimer-s-disease-among-early-41139687
Lecanemab, an anti-amyloid monoclonal antibody, has been approved for treatment of early Alzheimer's disease. However, real-world data remain limited regarding use. Using data from a large national health plan with primarily …
-
Lecanemab and Donanemab Combination Therapy for Alzheimer’s Disease-The Cocktail May Work Even Better TogetherResearch summary
Research summaries · alzhub.org/study/lecanemab-and-donanemab-combination-therapy-for-alzheimers-disease-41773886
Lecanemab and Donanemab are two new FDA-approved antiamyloid immunotherapies that are Alzheimer disease modifying agents. They do not work on the same target, however. While Lecanemab targets pathologic amyloid protofibrils, …
-
Lecanemab, aducanumab, and donanemab bind the same human Alzheimer disease Aβ aggregates at different epitopesResearch summary
Research summaries · alzhub.org/study/lecanemab-aducanumab-and-donanemab-bind-the-same-human-alzheimer-41435407
Abstract Background Lecanemab, donanemab, and aducanumab all bind to aggregates of Aβ and all clear amyloid PET in clinical trials, but they are proposed to bind different forms of Aβ and cause amyloid related imaging abnormality …
-
Lecanemab-Associated Amyloid-β Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer's DiseaseResearch summary
Research summaries · alzhub.org/study/lecanemab-associated-amyloid-protofibril-in-cerebrospinal-fluid-39761671
Objective The Clarity AD phase III trial showed that lecanemab reduced amyloid markers in early Alzheimer's disease (AD) and resulted in less decline on measures of cognition and function than placebo. Herein, we aimed to …
How this search works
There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.
One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.
28381 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-05. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.